IPM Take
Premature menopause has traditionally lived in the reproductive-health section of the medical record. Cardiovascular medicine is increasingly making the case that it should not stay there.
A new analysis from the Atherosclerosis Risk in Communities study followed more than 4,700 postmenopausal women for an average of more than two decades and found that menopause before age 40 was associated with higher subsequent cardiovascular disease and coronary heart disease risk.
What makes the study particularly interesting is not simply that the association exists. That relationship has been recognised before. The new question is why it exists.
Women with premature menopause had higher fasting insulin and greater insulin resistance despite no significant difference in fasting glucose. Statistical mediation analyses suggested that insulin resistance accounted for about one fifth of the association between premature menopause and later cardiovascular disease.
That does not mean insulin resistance has been proven to cause the excess cardiovascular risk, and it certainly does not mean a new screening test or treatment pathway is ready for implementation. The findings come from an observational conference abstract, menopause timing was self-reported, and most of the association remained unexplained.
But the policy direction is becoming clearer.
The 2026 ACC/AHA dyslipidaemia guideline already recognises early and premature menopause as reproductive risk markers that can help personalise cardiovascular risk assessment. The new ARIC findings strengthen the argument that menopause history should not disappear once reproductive care ends.
A woman who reaches menopause at 38 may not look high risk according to a short-term cardiovascular calculator.
Her life-course risk may tell a different story.
Executive Summary
A new analysis presented at the 2026 Annual Meeting of The Menopause Society examined whether insulin resistance could partly explain the relationship between premature menopause and later cardiovascular disease.
Researchers analysed 4,710 postmenopausal women aged 45 to 64 years from the Atherosclerosis Risk in Communities study who had no cardiovascular disease at baseline. Menopause timing was classified as premature before age 40, early between 40 and 44, or occurring at age 45 or later.
During an average follow-up of 21.4 years, researchers recorded 1,570 cardiovascular events.
Compared with women whose menopause occurred at age 45 or later, women with premature menopause had a 19% higher relative risk of composite cardiovascular disease and a 30% higher relative risk of coronary heart disease after adjustment for demographic, lifestyle and reproductive factors.
Premature menopause was not significantly associated with stroke or heart failure, while menopause between ages 40 and 44 was not significantly associated with any of the cardiovascular outcomes studied.
The metabolic findings added another layer. Women with premature menopause had 9.3% higher fasting insulin levels and 9.9% higher insulin resistance measured using HOMA-IR, while fasting glucose did not differ significantly.
Mediation analyses estimated that insulin and HOMA-IR accounted for approximately 19% of the association between premature menopause and cardiovascular disease.
The results are observational and cannot establish that premature menopause causes insulin resistance, that insulin resistance causes the subsequent cardiovascular disease, or that treating insulin resistance would eliminate the excess risk.
They do, however, support a growing life-course approach to women’s cardiovascular prevention in which menopause timing is considered alongside conventional risk factors rather than being treated solely as reproductive history.
Why it matters
- HTA bodies: The study illustrates the growing importance of sex-specific and reproductive variables in risk stratification. Before additional biomarkers such as fasting insulin or HOMA-IR enter formal assessment pathways, prospective evidence will be needed to show that they improve prediction beyond conventional cardiovascular risk factors and lead to interventions that improve outcomes.
- Payers: Premature menopause affects a relatively small proportion of women, which could make targeted cardiovascular prevention feasible if higher-risk pathways are validated. The more immediate question is whether existing preventive services consistently recognise reproductive risk history and provide appropriate assessment of blood pressure, lipids, glycaemia and other modifiable factors.
- Industry / innovation partners: Risk-prediction tools increasingly compete on their ability to capture information conventional calculators miss. Menopause timing, pregnancy complications and other reproductive markers could become increasingly relevant to personalised cardiovascular models, but adding variables is valuable only if they improve clinical decisions rather than simply make algorithms more complex.
For many women, the age at which menopause occurs is documented once, discussed in the context of reproductive or bone health and then gradually loses visibility as care moves into later adulthood.
Cardiovascular medicine is giving clinicians a reason to keep looking at that date.
A new analysis from the long-running Atherosclerosis Risk in Communities study suggests that women who experienced menopause before age 40 carried higher cardiovascular risk for more than two decades afterwards, and that part of this relationship may run through insulin resistance.
The study included 4,710 postmenopausal women who were between 45 and 64 years old at baseline and had no known cardiovascular disease. Researchers divided them according to whether menopause had occurred before age 40, between 40 and 44, or at age 45 or later, then followed cardiovascular outcomes for an average of 21.4 years.
Over that period, 1,570 cardiovascular events occurred.
Women who had experienced premature menopause had a 19% higher relative risk of the composite cardiovascular outcome than women whose menopause occurred at age 45 or later. The association was stronger for coronary heart disease, where relative risk was 30% higher.
The signal was not uniform across every cardiovascular outcome. Premature menopause was not significantly associated with stroke or heart failure, while menopause occurring between 40 and 44 years was not significantly associated with the composite cardiovascular outcome, coronary disease, stroke or heart failure.
That distinction is important because it argues against treating every earlier menopause transition as though it confers the same level of cardiovascular risk.
It also makes the mechanism more interesting.
Researchers looked specifically at fasting glucose, fasting insulin and the homeostasis model assessment of insulin resistance, commonly known as HOMA-IR, to determine whether altered glucose metabolism might sit somewhere between premature menopause and cardiovascular disease.
Women with menopause before age 40 had insulin concentrations approximately 9.3% higher than women whose menopause occurred at 45 or later, while HOMA-IR was approximately 9.9% higher.
Fasting glucose, however, was not significantly different.
That pattern matters because glucose and insulin are telling clinicians related but different things.
The body can maintain a relatively normal fasting glucose concentration for years by producing more insulin. In that setting, glucose may look reassuring while insulin sensitivity has already deteriorated. The ARIC analysis therefore raises the possibility that some of the metabolic difference associated with premature menopause may emerge before fasting hyperglycaemia becomes apparent.
But the study does not prove that sequence.
Its mediation analysis estimated that insulin levels accounted for approximately 19% of the relationship between premature menopause and cardiovascular disease, with HOMA-IR producing a nearly identical estimate of 19.3%.
Statistical mediation can suggest a plausible pathway, but it cannot transform observational data into a biological experiment. Menopause timing, insulin resistance and cardiovascular disease share multiple potential influences, including genetics, adiposity, smoking, socioeconomic factors, inflammation and other health conditions.
The majority of the observed association also remained unexplained.
Insulin resistance therefore appears to be one possible piece of a larger cardiovascular story rather than a complete mechanism.
That is consistent with what is already known about premature menopause.
Loss of ovarian function at a younger age results in a longer lifetime exposure to the postmenopausal hormonal environment, while menopause itself is associated with changes in body composition, lipid metabolism, vascular function and metabolic health. Earlier natural menopause has repeatedly been associated with greater cardiovascular risk in epidemiological research.
The policy problem is that reproductive information has historically sat at the edge of mainstream cardiovascular assessment.
Conventional cardiovascular risk models are built heavily around age, cholesterol, blood pressure, smoking, diabetes and kidney function. Those variables are important, but they do not fully capture the biological history that brought a woman to her current risk state.
Pregnancy complications have exposed a similar gap.
Preeclampsia, gestational diabetes, gestational hypertension and preterm birth can occur decades before overt cardiovascular disease but provide information about later risk. Premature menopause belongs increasingly to the same life-course framework.
The 2026 ACC/AHA dyslipidaemia guideline makes that transition explicit. It lists reproductive risk markers, including early menopause before age 45 and particularly premature menopause before 40, as factors that can help personalise cardiovascular risk assessment when clinicians are considering preventive lipid-lowering therapy.
That does not mean every woman with premature menopause should automatically receive a statin.
It means the history should change the conversation.
A woman reaching menopause at 38 may still have low calculated 10-year cardiovascular risk when she is 45 because chronological age exerts such a powerful influence on short-term risk estimates. Yet her exposure to risk will accumulate for decades.
That is exactly the situation in which life-course information becomes useful.
Premature menopause could prompt clinicians to pay closer attention to blood pressure, smoking, weight distribution, lipids, glucose regulation, physical activity and family history rather than waiting until traditional risk thresholds are crossed later in life.
The new insulin findings may eventually refine that approach further, but they are not yet sufficient to justify routine insulin or HOMA-IR screening for every woman with premature menopause.
Before that happens, researchers would need to demonstrate that those measurements improve cardiovascular prediction beyond conventional factors and, more importantly, that acting on the results changes clinical outcomes.
There is also a treatment question that the current study does not answer.
The analysis should not be interpreted as evidence that menopause hormone therapy prevents the cardiovascular risk associated with premature menopause. Decisions about hormone therapy in premature ovarian insufficiency or early menopause involve broader considerations, including symptom control, bone health and the consequences of prolonged estrogen deficiency, but this observational analysis did not test hormone therapy as a cardiovascular prevention strategy.
Nor does it show that interventions directly targeting insulin resistance will eliminate the cardiovascular excess associated with premature menopause.
The clearest immediate implication is therefore less dramatic but more actionable: ask about reproductive history and keep it visible.
Women often move through fragmented healthcare systems in which reproductive care, primary care, endocrinology and cardiology occupy separate clinical lanes. A menopause event documented by a gynaecologist in a woman’s thirties may never meaningfully enter cardiovascular decision-making two decades later.
That fragmentation is increasingly difficult to defend as reproductive events accumulate evidence as markers of later cardiovascular vulnerability.
The ARIC findings add a mechanistic clue to that argument.
Premature menopause was associated not only with later coronary disease but also with greater insulin resistance, even while fasting glucose remained similar. If future studies reproduce that pattern, the metabolic consequences of premature menopause may prove detectable before conventional glucose thresholds announce themselves.
For now, the study remains conference-level evidence and should be treated accordingly. Menopause timing was self-reported, causality cannot be established and the findings require replication and full peer-reviewed publication.
But the direction of travel is difficult to miss.
Cardiovascular prevention is gradually moving away from the idea that women’s reproductive history belongs to a separate chapter of medicine.
Menopause before 40 may occur decades before a cardiovascular event, which is precisely why it matters: prevention has more value when the warning signal appears early enough to act on it.
